Based on our examination of basic and clinical studies, we hypothesize that angiotensin-1 receptor (AT1R) inverse agonist drugs may be a promising tool in the management of COVID-19 patients, avoiding complications and the development of the severe phase of the disease, and the subsequent poor outcomes. This evidence concerns the gene AGTR1 and COVID-19.